Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers

James A. Bourgeois, Andreea L. Seritan, E. Melina Casillas, David R Hessl, Andrea Schneider, Ying Yang, Inderjeet Kaur, Jennifer B. Cogswell, Danh V. Nguyen, Randi J Hagerman

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

Objective: The authors studied the lifetime prevalence of DSM-IV-TR psychiatric disorders in a population of adults with the fragile X premutation. Method: The Structured Clinical Interview for DSM-IV was conducted, from 2007-2008, in 85 individuals with the fragile X premutation, 47 with the fragile X- associated tremor/ataxia syndrome (FXTAS; 33 male, 14 female; mean age = 66 years) and 38 without FXTAS (16 male, 22 female; mean age = 52 years). Lifetime prevalence for mood and anxiety disorders among carriers with and without FXTAS was compared to available age-specific population estimates from the National Comorbidity Survey Replication (NCS-R). Results: Among participants with FXTAS, 30 (65%) met lifetime DSM-IV-TR criteria for a mood disorder; 24 (52%) met lifetime DSM-IV-TR criteria for an anxiety disorder. Among the non-FXTAS participants, there were 15 instances of lifetime mood disorder (42%) and 18 of lifetime anxiety disorder (47%). When compared to age-specific NCS-R data, the lifetime prevalences of any mood disorder (P < .0001), major depressive disorder (P < .0001), any anxiety disorder (P < .0001), panic disorder (P = .006), specific phobia (P = .0003), and posttraumatic stress dis order (P = .004) were significantly higher in participants with FXTAS. The lifetime rates of social phobia in individuals with the premutation without FXTAS were significantly higher than NCS-R data (P = .001). Conclusions: This sample of carriers of the fragile X premutation had a notably high lifetime risk of mood and anxiety disorders. Mood and anxiety disorders may be part of the clinical phenotype of the fragile X premutation conditions, especially in carriers with FXTAS. Clinicians encountering these patients are advised to consider FXTAS as a neuropsychiatric syndrome as well as a neurologic disorder.

Original languageEnglish (US)
Pages (from-to)175-182
Number of pages8
JournalJournal of Clinical Psychiatry
Volume72
Issue number2
DOIs
StatePublished - Feb 2011

Fingerprint

Anxiety Disorders
Mood Disorders
Diagnostic and Statistical Manual of Mental Disorders
Comorbidity
Panic Disorder
Major Depressive Disorder
Nervous System Diseases
Population
Psychiatry
Interviews
Phenotype
Surveys and Questionnaires

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. / Bourgeois, James A.; Seritan, Andreea L.; Casillas, E. Melina; Hessl, David R; Schneider, Andrea; Yang, Ying; Kaur, Inderjeet; Cogswell, Jennifer B.; Nguyen, Danh V.; Hagerman, Randi J.

In: Journal of Clinical Psychiatry, Vol. 72, No. 2, 02.2011, p. 175-182.

Research output: Contribution to journalArticle

Bourgeois, JA, Seritan, AL, Casillas, EM, Hessl, DR, Schneider, A, Yang, Y, Kaur, I, Cogswell, JB, Nguyen, DV & Hagerman, RJ 2011, 'Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers', Journal of Clinical Psychiatry, vol. 72, no. 2, pp. 175-182. https://doi.org/10.4088/JCP.09m05407blu
Bourgeois, James A. ; Seritan, Andreea L. ; Casillas, E. Melina ; Hessl, David R ; Schneider, Andrea ; Yang, Ying ; Kaur, Inderjeet ; Cogswell, Jennifer B. ; Nguyen, Danh V. ; Hagerman, Randi J. / Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. In: Journal of Clinical Psychiatry. 2011 ; Vol. 72, No. 2. pp. 175-182.
@article{861b931c6144475fbb21d0edfe8e8a17,
title = "Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers",
abstract = "Objective: The authors studied the lifetime prevalence of DSM-IV-TR psychiatric disorders in a population of adults with the fragile X premutation. Method: The Structured Clinical Interview for DSM-IV was conducted, from 2007-2008, in 85 individuals with the fragile X premutation, 47 with the fragile X- associated tremor/ataxia syndrome (FXTAS; 33 male, 14 female; mean age = 66 years) and 38 without FXTAS (16 male, 22 female; mean age = 52 years). Lifetime prevalence for mood and anxiety disorders among carriers with and without FXTAS was compared to available age-specific population estimates from the National Comorbidity Survey Replication (NCS-R). Results: Among participants with FXTAS, 30 (65{\%}) met lifetime DSM-IV-TR criteria for a mood disorder; 24 (52{\%}) met lifetime DSM-IV-TR criteria for an anxiety disorder. Among the non-FXTAS participants, there were 15 instances of lifetime mood disorder (42{\%}) and 18 of lifetime anxiety disorder (47{\%}). When compared to age-specific NCS-R data, the lifetime prevalences of any mood disorder (P < .0001), major depressive disorder (P < .0001), any anxiety disorder (P < .0001), panic disorder (P = .006), specific phobia (P = .0003), and posttraumatic stress dis order (P = .004) were significantly higher in participants with FXTAS. The lifetime rates of social phobia in individuals with the premutation without FXTAS were significantly higher than NCS-R data (P = .001). Conclusions: This sample of carriers of the fragile X premutation had a notably high lifetime risk of mood and anxiety disorders. Mood and anxiety disorders may be part of the clinical phenotype of the fragile X premutation conditions, especially in carriers with FXTAS. Clinicians encountering these patients are advised to consider FXTAS as a neuropsychiatric syndrome as well as a neurologic disorder.",
author = "Bourgeois, {James A.} and Seritan, {Andreea L.} and Casillas, {E. Melina} and Hessl, {David R} and Andrea Schneider and Ying Yang and Inderjeet Kaur and Cogswell, {Jennifer B.} and Nguyen, {Danh V.} and Hagerman, {Randi J}",
year = "2011",
month = "2",
doi = "10.4088/JCP.09m05407blu",
language = "English (US)",
volume = "72",
pages = "175--182",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "2",

}

TY - JOUR

T1 - Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers

AU - Bourgeois, James A.

AU - Seritan, Andreea L.

AU - Casillas, E. Melina

AU - Hessl, David R

AU - Schneider, Andrea

AU - Yang, Ying

AU - Kaur, Inderjeet

AU - Cogswell, Jennifer B.

AU - Nguyen, Danh V.

AU - Hagerman, Randi J

PY - 2011/2

Y1 - 2011/2

N2 - Objective: The authors studied the lifetime prevalence of DSM-IV-TR psychiatric disorders in a population of adults with the fragile X premutation. Method: The Structured Clinical Interview for DSM-IV was conducted, from 2007-2008, in 85 individuals with the fragile X premutation, 47 with the fragile X- associated tremor/ataxia syndrome (FXTAS; 33 male, 14 female; mean age = 66 years) and 38 without FXTAS (16 male, 22 female; mean age = 52 years). Lifetime prevalence for mood and anxiety disorders among carriers with and without FXTAS was compared to available age-specific population estimates from the National Comorbidity Survey Replication (NCS-R). Results: Among participants with FXTAS, 30 (65%) met lifetime DSM-IV-TR criteria for a mood disorder; 24 (52%) met lifetime DSM-IV-TR criteria for an anxiety disorder. Among the non-FXTAS participants, there were 15 instances of lifetime mood disorder (42%) and 18 of lifetime anxiety disorder (47%). When compared to age-specific NCS-R data, the lifetime prevalences of any mood disorder (P < .0001), major depressive disorder (P < .0001), any anxiety disorder (P < .0001), panic disorder (P = .006), specific phobia (P = .0003), and posttraumatic stress dis order (P = .004) were significantly higher in participants with FXTAS. The lifetime rates of social phobia in individuals with the premutation without FXTAS were significantly higher than NCS-R data (P = .001). Conclusions: This sample of carriers of the fragile X premutation had a notably high lifetime risk of mood and anxiety disorders. Mood and anxiety disorders may be part of the clinical phenotype of the fragile X premutation conditions, especially in carriers with FXTAS. Clinicians encountering these patients are advised to consider FXTAS as a neuropsychiatric syndrome as well as a neurologic disorder.

AB - Objective: The authors studied the lifetime prevalence of DSM-IV-TR psychiatric disorders in a population of adults with the fragile X premutation. Method: The Structured Clinical Interview for DSM-IV was conducted, from 2007-2008, in 85 individuals with the fragile X premutation, 47 with the fragile X- associated tremor/ataxia syndrome (FXTAS; 33 male, 14 female; mean age = 66 years) and 38 without FXTAS (16 male, 22 female; mean age = 52 years). Lifetime prevalence for mood and anxiety disorders among carriers with and without FXTAS was compared to available age-specific population estimates from the National Comorbidity Survey Replication (NCS-R). Results: Among participants with FXTAS, 30 (65%) met lifetime DSM-IV-TR criteria for a mood disorder; 24 (52%) met lifetime DSM-IV-TR criteria for an anxiety disorder. Among the non-FXTAS participants, there were 15 instances of lifetime mood disorder (42%) and 18 of lifetime anxiety disorder (47%). When compared to age-specific NCS-R data, the lifetime prevalences of any mood disorder (P < .0001), major depressive disorder (P < .0001), any anxiety disorder (P < .0001), panic disorder (P = .006), specific phobia (P = .0003), and posttraumatic stress dis order (P = .004) were significantly higher in participants with FXTAS. The lifetime rates of social phobia in individuals with the premutation without FXTAS were significantly higher than NCS-R data (P = .001). Conclusions: This sample of carriers of the fragile X premutation had a notably high lifetime risk of mood and anxiety disorders. Mood and anxiety disorders may be part of the clinical phenotype of the fragile X premutation conditions, especially in carriers with FXTAS. Clinicians encountering these patients are advised to consider FXTAS as a neuropsychiatric syndrome as well as a neurologic disorder.

UR - http://www.scopus.com/inward/record.url?scp=79951971920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951971920&partnerID=8YFLogxK

U2 - 10.4088/JCP.09m05407blu

DO - 10.4088/JCP.09m05407blu

M3 - Article

C2 - 20816038

AN - SCOPUS:79951971920

VL - 72

SP - 175

EP - 182

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 2

ER -